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Common variable immunodeficiency disorders (CVIDs) are the most frequent sympto-
matic primary immune deficiency condition in adults. The genetic basis for the condition
is not known and no single clinical feature or laboratory test can establish the diagnosis; it
has been a diagnosis of exclusion. In areas of uncertainty, diagnostic criteria can provide
valuable clinical information. Here, we compare the revised European society of immune
deficiencies (ESID) registry (2014) criteria with the diagnostic criteria of Ameratunga et al.
(2013) and the original ESID/pan American group for immune deficiency (ESID/PAGID 1999)
criteria.The ESID/PAGID (1999) criteria either require absent isohemagglutinins or impaired
vaccine responses to establish the diagnosis in patients with primary hypogammaglobu-
linemia. Although commonly encountered, infective and autoimmune sequelae of CVID
were not part of the original ESID/PAGID (1999) criteria. Also excluded were a series of
characteristic laboratory and histological abnormalities, which are useful when making the
diagnosis. The diagnostic criteria of Ameratunga et al. (2013) for CVID are based on these
markers. The revised ESID registry (2014) criteria for CVID require the presence of symp-
toms as well as laboratory abnormalities to establish the diagnosis. Once validated, criteria
for CVID will improve diagnostic precision and will result in more equitable and judicious
use of intravenous or subcutaneous immunoglobulin therapy.
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INTRODUCTION
Common variable immunodeficiency disorders (CVIDs) are the
most frequent symptomatic primary immune deficiency disorder
in adults. While most patients suffer recurrent infections (1–
5), there is also an increased risk of autoimmune disorders and
malignancy because of immune dysregulation. CVID is likely to
represent a heterogeneous group of polygenic disorders (6).
Although some patients have symptoms dating back to early
childhood (7), the hallmark of CVID is primary hypogamma-
globulinemia, which is a consequence of late onset antibody failure
(LOAF). The majority of adult patients with CVID have IgG levels
below 5 g/l (5). Most patients also have reduced or undetectable
IgA and/or IgM levels (1, 8). Other laboratory features may include
reduced switched memory B cells and/or increased numbers of
CD21 low B cells in the periphery (9). A subgroup of patients with
severe T-cell defects, originally included within the spectrum of
CVID, are now defined separately as late onset combined immune
deficiency (LOCID) (10).
In addition to the laboratory features outlined above,
many patients have characteristic histological lesions includ-
ing a sarcoidosis-like granulomatous disorder, nodular lymphoid
hyperplasia of the gut, nodular regenerative hyperplasia of the
liver, or lymphoid interstitial pneumonitis of the lungs (11–16).
Absence of plasma cells in gastrointestinal biopsies is another
characteristic finding in the majority of CVID patients (17–19).
DIAGNOSIS OF CVID
It can be very difficult to determine which patients are suffering
from CVID and require intravenous immunoglobulin (IVIG) or
subcutaneous immunoglobulin (SCIG) replacement. IVIG/SCIG
treatment can substantially improve both quality of life (20) and
longevity in patients with CVID. This underscores the importance
of accurate diagnostic criteria for CVID (21).
Here, we compare the original (1999) European society of
immune deficiencies (ESID)/pan American group for immune
deficiency (PAGID) criteria, the Ameratunga et al. (2013) crite-
ria and the revised ESID registry (2014) criteria (Tables 1–3).
We have previously described in detail the evidence base for the
Ameratunga et al. (2013) criteria (21). It is necessary to provide
an abbreviated version of these criteria here to allow comparison
with the revised ESID registry (2014) criteria. We have devoted
similar space to each of these criteria.
REVIEW OF THE ESID/PAGID (1999) CRITERIA FOR CVID
According to the ESID/PAGID (1999) criteria, CVID is a diag-
nosis of exclusion (Table 1) (33). Patients were required to have
an IgG level below 7–8 g/l [2 SD below the mean, or more accu-
rately, below the 97.5th percentile, as immunoglobulin levels are
not normally distributed (34)], as well as impaired vaccine chal-
lenge responses or absent isohemagglutinins and other secondary
causes of hypogammaglobulinemia were to be excluded. The
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Table 1 |The original ESID/PAGID (1999) criteria for probable and
possible CVID.
Probable
Probable CVID
Male or female patient who has a marked decrease of IgG (at least 2 SD
below the mean for age) and a marked decrease in at least one of the
isotypes IgM or IgA, and fulfils all of the following criteria:
• Onset of immunodeficiency at >2 years of age
• Absent isohemagglutinins and/or poor response to vaccines
• Defined causes of hypogammaglobulinemia have been excluded
Possible CVID
Male or female patient who has a marked decrease (at least 2 SD below
the mean for age) in at least one of the major isotypes (IgM, IgG, and IgA)
and fulfils all of the following criteria:
1. Onset of immunodeficiency at >2 years of age
2. Absent isohemagglutinins and/or poor response to vaccines
3. Defined causes of hypogammaglobulinemia have been excluded
criteria did not include the characteristic histological features of
the disorder or clinical sequelae resulting from the immune system
failure (ISF).
Since that time, there have been major advances in the under-
standing of CVID. The majority of CVID patients have impaired
memory B cell function with a reduction in switched memory B
cells (9). In the last decade, there have been several genetic dis-
coveries in patients with CVID-like conditions. Rare patients with
monogenic defects of CD19, CD20, CD21, CD81, and ICOS have
been identified (35–38). If identified by molecular diagnostic stud-
ies (39), these patients are, however, no longer classified as having
CVID and are removed from further consideration of the disorder
(40, 41). Genetic alterations from genome wide association studies,
including copy number variations (42) and sequence variations in
genes such as TACI, BAFF receptor, and MSH5 may predispose
to CVID. Mutations of TACI, BAFF receptor, and MSH5 are also
found in healthy individuals, but at lower frequency (28, 31, 43).
The ESID/PAGID (1999) criteria require IgG levels to be below
2 SD of the mean (Table 1). This means that 2.5% of the gen-
eral population would meet this criterion (23). There is gen-
eral agreement with the third ESID/PAGID (1999) criterion that
other secondary causes of hypogammaglobulinemia including
drug-induced disorders need to be excluded (22, 44, 45).
Perhaps the greatest difficulty with the ESID/PAGID (1999)
criteria is the requirement for poor responses to vaccines. The
ESID/PAGID (1999) criteria do not specify which vaccines should
be used and there are significant variations in vaccine proto-
cols in different studies (46, 47). Therefore, patients with trivial
hypogammaglobulinemia with mildly impaired diphtheria anti-
body responses could be classified as having CVID. Poor responses
to the diphtheria vaccine are common, even in normal persons,
particularly with increasing age (23).
It is likely many patients with CVID have already gen-
erated vaccine-specific memory B cells following childhood
immunization prior to LOAF. Therefore, assessing booster
Table 2 | New diagnostic criteria (Ameratunga et al., 2013) for CVID.
A Must meet all major criteria
• Hypogammaglobulinemia IgG<5 g/l (5)
• No other cause identified for immune defect (22)
• Age>4 years (23)
B Sequelae directly attributable to immune system failure (ISF) (one or
more)
• Recurrent, severe, or unusual infections
• Poor response to antibiotics
• Breakthrough infections in spite of prophylactic antibiotics
• Infections in spite of appropriate vaccination, e.g., HPV disease
• Bronchiectasis and/or chronic sinus disease
• Inflammatory disorders or autoimmunity (24)
C Supportive laboratory evidence (three or more criteria)
• Concomitant reduction or deficiency of IgA (<0.8 g/l) and/or IgM
(0.4 g/l) (1, 4)
• Presence of B cells but reduced memory B cell subsets and/or
increased CD21 low subsets by flow cytometry (9)
• IgG3 deficiency (<0.2 g/l) (25, 26)
• Impaired vaccine responses compared to age-matched
controls (27)
• Transient vaccine responses compared with age-matched controls
(28, 29)
• Absent isohemagglutinins (if not blood group AB) (30)
• Serological evidence of significant autoimmunity, e.g., Coombs test
• Sequence variations of genes predisposing to CVID, e.g., TACI,
BAFFR, MSH5, etc. (31, 32)
D Presence of relatively specific histological markers of CVID (not
required for diagnosis but presence increases diagnostic certainty, in
the context of category A and B criteria)
• Lymphoid interstitial pneumonitis (11)
• Granulomatous disorder (12, 13)
• Nodular regenerative hyperplasia of the liver (14, 15)
• Nodular lymphoid hyperplasia of the gut (16)
• Absence of plasma cells on gut biopsy (17, 18)
Meeting criteria in categories ABC or ABD indicates probable CVID. Patients
meeting criteria ABC and ABD should be treated with IVIG/SCIG (Figure 1).
Patients meeting criteria A alone, AB or AC or AD but not B, are termed possible
CVID. Some of these patients may need to be treated with IVIG/SCIG. Patients
with levels of IgG> 5 g/l, not meeting any other criteria are termed hypogamma-
globulinemia of uncertain significance (HGUS) (21).These diagnostic criteria must
be applied sequentially as none are specific individually.
responses to childhood vaccines may be diagnostically misleading.
This may explain why a significant minority of patients with pre-
sumed CVID have protective responses to tetanus toxoid and
Pneumovax® (48, 49). It is also debatable if the response to highly
immunogenic proteins such as tetanus toxoid, administered with
adjuvant, is a valid and reliable predictor of a protective response
to pathogens in vivo (21). Specific concerns about using vaccines
to assess the immune response are shown in Table 4.
The use of neoantigens such as rabies vaccine, typhoid vaccine,
and experimental vaccines such as ψX174 to assess LOAF may be
more predictive of an immune defect as patients are unlikely to
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Table 3 | Revised ESID (2014) diagnostic criteria for CVID.
At least one of the following:
• Increased susceptibility to infection
• Autoimmune manifestations
• Granulomatous disease
• Unexplained polyclonal lymphoproliferation
• Affected family member with antibody deficiency
AND marked decrease of IgG and marked decrease of IgA with or
without low IgM levels (measured at least twice; <2 SD of the
normal levels for their age);
AND at least one of the following:
• Poor antibody response to vaccines (and/or absent
isohemagglutinins); i.e., absence of protective levels despite
vaccination where defined
• Low switched memory B cells (<70% of age-related normal value)
AND secondary causes of hypogammaglobulinemia have been
excluded (see separate list)
AND diagnosis is established after the fourth year of life (but
symptoms may be present before)
AND no evidence of profound T-cell deficiency, defined as two out of
the following (y= year of life):
• CD4 numbers/microliter: 2–6 y<300, 6–12 y<250, >12 y<200
• % Naive CD4: 2–6 y<25%, 6–16 y<20%, >16 y<10%
• T-cell proliferation absent
http://esid.org/Working-Parties/Registry/Diagnosis-criteria.
have previously encountered these antigens (54). However, there
have been concerns about risks associated with the rabies vaccine
(54) and the typhoid vaccine is not yet widely used. The ψx174
vaccine has not been registered by the FDA and cannot be used in
routine clinical practice (67).
The difficulty with diagnosis is illustrated in a recent study in
which a new category of idiopathic primary hypogammaglob-
ulinemia was proposed for symptomatic patients who did not
meet the ESID/PAGID (1999) criteria for CVID (68). In spite
of not meeting the ESID/PAGID (1999) criteria, many of these
patients were treated with immunoglobulin. There is thus a dis-
cord between diagnosis and treatment in many patients with
hypogammaglobulinemia/CVID.
The ESID/PAGID (1999) criteria do not specify the need for
symptoms to establish the diagnosis. Therefore, important clin-
ical manifestations and complications may not be obvious from
different parts of the world, when using these criteria. This was
illustrated in recent CVID studies, where there were wide varia-
tions in complications leading to different clinical phenotypes as
well as bronchiectasis in countries within the European Union as
well as the United States (4, 7, 69).
It is accepted that these criteria are relatively simple and could
be used to diagnose patients in developing countries. The major
difficulty is the interpretation of vaccine responses (Table 4),
which is a pivotal component of these criteria. We are also
concerned that the application of relatively simple criteria to a
complex set of disorders will result in inaccuracies, as evidenced
by the need for a new category of disorders, idiopathic primary
hypogammaglobulinemia, described above. We are thus left with
criteria that can be difficult to measure and interpret. Several emi-
nent authors have expressed concern about the need for revised
diagnostic criteria for CVID (70, 71).
NEW DIAGNOSTIC CRITERIA FOR CVID
We recently proposed new diagnostic criteria for CVID (Table 2)
(21). Treatment recommendations are closely linked to these diag-
nostic criteria (Figure 1). The Ameratunga et al. (2013) criteria
emphasize both the clinical and laboratory sequelae of ISF in these
patients (72).
In order to qualify as having probable CVID, patients must meet
criteria in categories A, B, and C or D (Table 2). It is important
for these criteria to be applied sequentially, as each subsequent
category confers increasing specificity (Figure 1). A threshold of
5 g/l for IgG has been set for adults as this is the cut-off used in the
French DEFI study (5). Patients must be older than 4 years of age
and must not have a secondary cause for their hypogammaglobu-
linemia. If patients do not meet category A criteria, other criteria
do not apply and a diagnosis of CVID cannot be entertained
(Figure 1).
The most important feature of these criteria is clinical evidence
of ISF (category B). Patients must have predisposition to infections
and/or autoimmune disease, as a direct result of their immune
defect. We have not been prescriptive about the numbers of upper
or lower respiratory tract infections, as these will be influenced by
the patient’s socio-demographic circumstances. While there may
be debate about the specificity of each criterion in category B, the
intention is to distinguish symptomatic patients from those who
are well. These symptomatic patients must have laboratory evi-
dence of immune dysfunction (category C) or the characteristic
histological findings (category D) associated with CVID (Table 2).
None of the category C criteria are specific but in combination
support the diagnosis of CVID. The majority of CVID patients will
have a reduction of IgA and/or IgM (1, 4). Most will have impaired
vaccine responses (49). It is, however, important to compare anti-
body responses to those of normal controls, as many CVID patients
who have received their primary immunization series are likely to
have developed memory B cells and are able to generate protective
antibody levels. Using protective antibody levels as eligibility cri-
teria for IVIG/SCIG is unacceptable in symptomatic patients as it
will exclude a significant proportion of patients who will benefit
from IVIG/SCIG treatment (48, 49).
Vaccine responses in normal controls have been published (50,
52, 53). Patients receiving a single booster dose of tetanus tox-
oid should achieve an antibody response of at least 1 IU/ml (50).
Although a response of 1 IU/ml has been suggested following diph-
theria immunization, our experience and original immunization
studies show that this vaccine is much less immunogenic than the
tetanus vaccine (50). Even otherwise healthy individuals may fail
to reach this level, particularly persons over 50 years of age. The
inclusion of diphtheria vaccine responses is thus problematic.
Adults and children receiving the Haemophilus influenzae type
B (HIB) vaccine should reach antibody levels of at least 1.0µg/ml
rather than the protective level of 0.15µg/ml (52, 53). Adults
receiving the Pneumovax® should achieve a protective level of
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Table 4 | Difficulties interpreting vaccine responses in CVID.
Tetanus toxoid Excellent immunogen (48)
Presence of memory B cells from childhood tetanus vaccination can make responses difficult to interpret in CVID
patients (21)
Results should be compared to normal individuals (50)
Uncertain validity of using simple antigens with adjuvant to gauge response to pathogens in vivo (28)
Diphtheria toxoid Poor immunogen (23)
Response should be compared with normal individuals (50)
Questionable validity of using simple antigens to gauge response to pathogens in vivo (28)
H. influenzae type B (HIB) There may be major differences between those who have not been immunized vs. those who have had this as part of
their routine vaccines (51)
Protective levels may not be logical: need to compare response with normal persons (52, 53)
Pneumovax® (PPV) Poor response in infants <2 years (54)
Differences in responses between middle aged and elderly adults (55)
Risk of unresponsiveness with repeated doses of PPV (56)
Difficulties in measuring antibody responses
Assays not standardized (8)
Cross-reactive carbohydrates can interfere with the assay (57, 58)
Some serotypes (serotype 3) are more immunogenic than others (6B and 23F) (54)
No external quality assurance program for the assay
Different platforms for pneumococcal antibody measurement may not be comparable (59)
Disagreement about protective antibody levels (60–62)
Mucosal protection may require higher antibody levels cf sepsis (63)
Diagnostic criteria have not been defined: at least five different criteria in the literature (64, 65)
Vaccine quality may vary: stability of conjugated vaccines. Lot to lot variation (54)
Up to 18% of CVID patients respond to PPV (49)
Use of Prevnar13® as part of routine vaccines will make is difficult to measure responses to carbohydrates
Other vaccines Not widely used, e.g., typhoid vaccine (54)
Many CVID patients may respond, e.g., meningococcal vaccine (66)
Experimental vaccines not approved by FDA ψ174 (67)
Risk of adverse reactions: e.g. rabies vaccines (54)
PPV, pneumococcal polysaccharide vaccine. PPV is administered to test response to T-cell independent carbohydrate antigens, while conjugated vaccines such as
HIB and toxoids test responses to T-cell dependent antigens.
1.3µg/ml for at least 70% of serotypes while children should reach
50% (64, 65). Adequate but transient vaccine responses are also
included in category C criteria (21, 29). This may reflect in vivo
failure of B cell memory in some patients.
We have included absent isohemagglutinins in these criteria
providing the patient is not blood group AB (30). Although absent
isohemagglutinins are part of the PAGID/ESID (1999) criteria, in
our experience it is rare for a diagnosis of CVID to be made or
for IVIG/SCIG to be prescribed, purely on the basis of absent
isohemagglutinins in a patient with reduced IgG levels.
Most patients with CVID have impaired memory B cells and
these constitute a diagnostic criterion in category C (9). It is, how-
ever, important for memory B cell subsets to be measured on at
least two occasions, as we have shown the numbers can vary on
repeat testing (73). Genetic predisposition (mutations of TACI,
BAFF receptor, MSH5, etc.) to CVID is included in category C
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FIGURE 1 |Treatment algorithm for CVID (21). Patients must meet all
major criteria in category A for consideration of CVID. Category B confirms
the presence of symptoms indicating immune system failure (ISF). To have
probable CVID, patients must also have supportive laboratory evidence of
immune system dysfunction (category C) or characteristic histological
lesions of CVID (category D). Patients with mild hypogammaglobulinemia
(IgG>5 g/l) are termed hypogammaglobulinemia of uncertain significance
(HGUS). Patients meeting category A criteria but not other criteria are
deemed to have possible CVID. Most patients with probable CVID are
likely to require IVIG/SCIG. Some patients with possible CVID who have
profound hypogammaglobulinemia will require IVIG/SCIG but most
patients with HGUS are unlikely to need IVIG/SCIG replacement.
diagnostic criteria (42). This criterion is primarily intended for
patients who may have been enrolled in clinical research studies.
In the interim, we strongly discourage routine sequencing of these
genes for diagnostic purposes until their utility is established.
Reduction or deficiency of IgG3 has been included in the new
diagnostic criteria. There is considerable peer-reviewed literature
suggesting IgG3 deficiency should be considered an important bio-
marker for a humoral immune defect (25, 26). We have included
serological manifestations of significant autoimmunity in cate-
gory C. This would include positive tests for lupus anticoagulant,
Coombs test, etc. In most large series of CVID patients there
are approximately 15% of patients who have severe autoimmu-
nity and some have minimal infections in spite of their profound
hypogammaglobulinemia. These patients will qualify as having
CVID according to the Ameratunga et al. (2013) criteria, providing
they have not been treated with rituximab.
Finally, some CVID patients have characteristic histological
findings, which have been included in the Ameratunga et al. (2013)
criteria (category D). These require biopsy for confirmation. In
the context of primary (category A), symptomatic (category B)
hypogammaglobulinemia, the presence of these relatively spe-
cific histological markers obviates the need to undertake vaccine
responses, measure memory B cells, etc. Most of the histological
criteria described in category D can occur with other disorders.
Because category D will only apply if patients have already met
category A and B criteria (Figure 1), this will confer specificity
for CVID. Category C and D criteria may serve as an useful check
list when assessing patients with hypogammaglobulinemia (21).
We have shown that careful review of category C and D cri-
teria may help to distinguish CVID from secondary causes of
hypogammaglobulinemia (46, 74, 75).
As in the past, a diagnostic rectal biopsy could be undertaken
to confirm the absence of plasma cells (19). Although a minority
of CVID patients have plasma cells, the absence of these cells in a
gut biopsy is a characteristic feature of CVID (21). Incorporating
histological features in the diagnostic criteria may be useful where
patients have already commenced IVIG/SCIG as there are risks in
stopping treatment to assess vaccine responses.
We have designated a category of possible CVID for those
patients meeting category A criteria (or AC or AD) but not
category B criteria (Figure 1). Some asymptomatic patients with
profound hypogammaglobulinemia may need to be treated with
IVIG/SCIG as they may be at risk of severe viral infections or
bacterial sepsis (28).
There are other patients who have mild hypogammaglobu-
linemia (IgG> 5 g/l) who are otherwise well or have only mild
symptoms. We have termed these patients hypogammaglobuline-
mia of uncertain significance (HGUS) (21). In the future, it may
be useful to sub classify HGUS patients depending on whether
(sHGUS) or not (aHGUS) they have symptoms attributable to
ISF. Prospective studies will indicate if the prognosis for these two
sub groups is different.
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The Ameratunga et al. (2013) criteria are intended primarily
for clinical use and we therefore felt it was important to link them
closely to treatment (Figure 1) (21). As with the Jones criteria for
acute rheumatic fever, CVID no longer needs to be a diagnosis of
exclusion.
REVISED ESID REGISTRY (2014) CRITERIA FOR CVID
The revised ESID registry (2014) criteria for probable CVID have
been recently released (http://esid.org/Working-Parties/Registry/
Diagnosis-criteria) and are shown in Table 3. These are struc-
tured in a similar way to the Ameratunga et al. (2013) criteria
but have not been given named categories. In contrast to the pre-
vious ESID/PAGID (1999) criteria, patients are required to have
symptoms of their immune deficiency or a family history of anti-
body deficiency to be eligible for a diagnosis of CVID. Increased
susceptibility to infection along with autoimmunity, unexplained
polyclonal lymphoproliferation, or granulomatous disease quali-
fies patients for further consideration of CVID. This is similar to
the Ameratunga et al. (2013) category B criteria, where a diagnosis
of CVID cannot be made in the absence of symptoms (21).
Symptomatic patients are required to have a marked decrease of
IgG as well as IgA and/or IgM. Again immunoglobulin levels 2 SD
below mean is required for the relevant population. Immunoglob-
ulin levels need to be repeated to confirm persistent reduction. This
would exclude transient reductions in immunoglobulins that can
sometimes be seen following viral infections or use of medications
(44). Although a large number of patients with mild hypogamma-
globulinemia will qualify for further investigation, the subsequent
criteria will increase the specificity of the diagnosis.
Patients with hypogammaglobulinemia must then have either
impaired antibody responses to vaccines and/or absent isohemag-
glutinins or reduced numbers of switched memory B cells for
further consideration of CVID. Unlike the previous ESID/PAGID
(1999) criteria, protective antibody levels are deemed to be
required.
Like the Ameratunga et al. (2013) criteria, the revised ESID
registry (2014) criteria do not specify which vaccines should be
used. It is likely vaccine protocols will evolve with the availabil-
ity and experience with new vaccines. As stated in Table 4, the
increasing use of Prevnar13® in routine childhood vaccine sched-
ules will make assessing pneumococcal polysaccharide responses
increasingly problematic. In contrast to the revised ESID registry
(2014) criteria, the Ameratunga et al. (2013) criteria require vac-
cine responses to be compared to the normal population, as a
significant proportion of presumed CVID patients have protective
antibody responses to tetanus and Pneumovax® (48, 49).
In contrast to the previous ESID/PAGID (1999) criteria, vaccine
responses do not play such a pivotal role in the revised ESID reg-
istry (2014) criteria for CVID. Like the Ameratunga et al. (2013)
criteria, it is therefore possible for patients to qualify as hav-
ing CVID with normal vaccine challenge responses if they have
either absent isohemagglutinins or reduced switched memory B
cell numbers (Table 3). The requirement for reduced memory B
cells in the revised ESID registry (2014) criteria is not manda-
tory and patients with absent B cells may still qualify for the
diagnosis if they have impaired vaccine responses and/or absent
isohemagglutinins.
As with all criteria described here, secondary causes of
hypogammaglobulinemia must be excluded. The previous
ESID/PAGID (1999) criteria specified 2 years as the eligible age for
diagnosis, while the Ameratunga et al. (2013) and revised ESID
registry criteria specify 4 years. The older age for diagnosis will
help exclude monogenic defects as well as many cases of transient
hypogammaglobulinemia of infancy. Unlike the ESID/PAGID
(1999) and Ameratunga et al. (2013) criteria, the revised ESID
registry (2014) criteria excludes severe T-cell defects from the spec-
trum of CVID, since these patients are deemed to have a combined
immune deficiency. It is likely the genetic defect will differ from
those with a largely humoral deficiency.
Granulomatous disease and lymphoproliferation are included
in the initial set of clinical criteria in the revised ESID registry
(2014) criteria (Table 3). This will require histological confir-
mation. Although not explicitly stated, our interpretation is that
lymphoproliferation will include nodular lymphoid hyperplasia
of the gut, nodular regenerative hyperplasia of the liver and lym-
phoid interstitial pneumonitis. These characteristic histological
features and are included in category D of the Ameratunga et al.
(2013) criteria. We assume an increase in CD21 low B cells may
be included in the lymphoproliferation criterion of the revised
ESID (2014) criteria. Like the Ameratunga et al. (2013) criteria,
secondary causes for the histological lesions will be excluded by
subsequent criteria. Nodular regenerative hyperplasia of the liver
for example can occur with azathioprine treatment.
Like the Ameratunga et al. (2013) criteria, the revised ESID reg-
istry (2014) criteria may allow the diagnosis of CVID in patients
who have already commenced IVIG/SCIG treatment. The pres-
ence of lymphoproliferation or reduced switched memory B cells
will allow the diagnosis as long as other criteria are satisfied.
This may obviate the need to stop IVIG/SCIG treatment to assess
vaccine responses. Neither the Ameratunga et al. (2013) criteria
nor the revised ESID (2014) registry criteria attempt to address
the complex situation of hypogammaglobulinemia/CVID asso-
ciated with malignancy. It can be very difficult to determine
if hypogammaglobulinemia/CVID is the cause or the effect of
malignancy.
Unlike the Ameratunga et al. (2013) criteria, the absence of
plasma cells is not included in the revised ESID registry (2014)
criteria. As indicated above, this is a useful feature in patients
who have already commenced IVIG/SCIG replacement and may
be identified by a diagnostic rectal biopsy. This is perhaps the most
useful histological marker of CVID. The Ameratunga et al. (2013)
criteria may be less useful if there are no characteristic histological
lesions in patients who have already commenced IVIG/SCIG treat-
ment. The emphasis on reduced switched memory B cells in the
revised ESID registry (2014) criteria may allow the diagnosis in
patients who have already commenced IVIG/SCIG. The revised
ESID registry (2014) criteria require switched memory B cells to
be below 70% of the normal population. Reference intervals will
therefore have to be established for each laboratory. Given the vari-
ability in these cells, the Ameratunga et al. (2013) criteria require
the assay to be repeated (73).
In comparison with the Ameratunga et al. (2013) criteria, tran-
sient vaccine responses are not included in the ESID registry
(2014) criteria or breakthrough infections in spite of prophylactic
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antibiotics. Failure of vaccines to prevent infections, e.g., human
papillomavirus is also not included in the revised criteria. The lat-
ter two may, however, be covered in the initial criterion of increased
susceptibility to infection in the revised ESID registry (2013) cri-
teria. Sequence variations in genes (TACI, BAFF receptor, MSH5,
etc.) predisposing to CVID and IgG3 deficiency are not included
in the revised ESID registry criteria (2014). Prospective studies will
determine the value of these criteria (21).
The previous ESID/PAGID (1999) criteria had a category of
possible CVID for patients not meeting the complete criteria for
CVID (Table 1). The revised ESID registry (2014) criteria have
a category of unclassified hypogammaglobulinemia for patients
who do not meet all the criteria for CVID. Studies of cohorts of
hypogammaglobulinemia patients will indicate if these categories
are equivalent to patients with HGUS in the Ameratunga et al.
(2013) criteria.
Like the previous ESID/PAGID (1999) criteria, diagnosis has
not been linked to eligibility to IVIG/SCIG treatment in the
revised ESID registry (2014) criteria, as these are intended for
clinical research rather than therapy. However, it is inevitable
these criteria will be used by clinicians to determine which
patients will qualify for immunoglobulin treatment in the
absence of specific national guidelines. Cohorts such as the NZ
CVID/hypogammaglobulinemia study will be important in deter-
mining if the revised ESID registry (2014) criteria can be used to
determine eligibility for treatment. It will be important to under-
take prospective head to head comparisons of these criteria in
hypogammaglobulinemic patients as we have done for memory B
cells in CVID (73).
The latter two (Ameratunga et al. 2013 and the revised ESID
registry 2014) criteria are based on the framework established
by the ESID/PAGID 1999 diagnostic criteria. Most patients diag-
nosed with CVID will have substantially reduced IgG, reduction
in other isotypes, impaired memory B cells, and impaired vac-
cine responses. The majority will thus qualify as having CVID by
all three criteria. It should be noted that none of these criteria
address partial antibody deficiency syndromes. This is an area that
will need to be addressed in future studies.
It will be important to determine how these criteria perform
in real-life clinical situations in ethnically diverse populations
across the globe. We expect most if not all patients deemed to
have idiopathic primary hypogammaglobulinemia, will qualify
as having CVID, which will secure their eligibility for treatment
with IVIG/SCIG (45, 68). Equally, it is hoped fewer asymptomatic
patients with mild hypogammaglobulinemia will be treated with
IVIG/SCIG.
Regardless of which criteria are used, it is essential that sound
clinical judgment is exercised when diagnosing and treating these
patients. It will be important to offer IVIG/SCIG for patients with
bronchiectasis with higher levels of IgG for example (sHGUS)
(76). Similarly, when assessing the cause of recurrent infections,
there may be other contributing factors, which could be potentially
treated in patients with hypogammaglobulinemia. The immune
defect may not be the dominant predisposing factor for infections
in some such individuals. Correcting functional or anatomical
predisposing factors such as chronic sinus disease may reduce
the number of infections and the patient may not need to be
treated with IVIG/SCIG in spite of the hypogammaglobulinemia.
This is why it is critical for these patients to be under the care of
experienced clinical immunologists.
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